Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Malaria diagnosis and prognosis with an electrokinetic-driven aptamer-based lateral flow assay.

Descrizione del progetto

Diagnosticare la malaria con lo smartphone

La malaria rimane una minaccia per la salute globale e i casi sono in aumento anche in Europa, per questo servono soluzioni diagnostiche e prognostiche su larga scala. Il progetto MalDiProT, finanziato dal programma di azioni Marie Skłodowska-Curie, si propone di migliorare la diagnosi decentrata sviluppando test diagnostici rapidi e sensibili. Sebbene la microscopia sia il gold standard per la conta dei parassiti, non è adatta all’uso decentrato. I ricercatori propongono di sviluppare un test a flusso laterale su carta in grado di misurare quantitativamente i biomarcatori della malaria in pochi minuti attraverso uno smartphone. Il test sarà sensibile e adatto a bassi livelli di parassiti, così da consentire una diagnosi e una prognosi precoci, in particolare nelle aree con scarse risorse.

Obiettivo

Malaria remains a public health concern, with 247 million cases and 619,000 deaths reported globally in 2021. Despite the increasing prevention and control measures driven by the World Health Organization (WHO), nearly half of the population is still at risk of malaria, with a reported increase in the incidence of imported malaria in European countries. To this end, implementing large-scale, high-coverage, early diagnosis, and accurate prognosis of severe malaria is critical to reducing the impact of malaria in Europe.
Due to its high sensitivity, parasite counting by microscopy observation is the current gold standard method. However, it is inappropriate for its application at the point of care (PoC). The rapid diagnostic tests (RDTs) based on lateral flow assay are the best option for PoC testing since they accomplish the REASSURED criteria WHO recommends. However, this method doesn't provide quantitative prognostic information and has proved low clinical sensitivity with low parasitemia samples (asymptomatic parasite carriers).
With this aim, I propose for the first time the development of a smartphone-powered electrophoretic-driven aptamer paper-based LFA capable of providing a quantitative measurement of 2 parasite (PfHRP2, pan-pLDH) and 2 host (ang-2 and CRP) malaria biomarkers within minutes. Compared to capillarity-driven LFA, the flow control by electrophoresis enables the application of different synergic strategies to increase assay sensitivity, such as integrated incubation steps and purification of interfering biomolecules. Highly specific aptamers will be developed by a fast and cost-effective microfluidic selection approach, used as bioreceptors with stability for electrokinetics. This will enable an early diagnosis and an accurate prognosis of malaria, reducing the risk of developing severe symptoms. Upon successfully validating the device in non-endemic areas (host institution), I expect its use in low-resource, malaria-endemic areas.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2023-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA
Contributo netto dell'UE
€ 187 858,56
Indirizzo
C ROSSELLO 132 PLANTA 05
08036 Barcelona
Spagna
Regione
Este Cataluña Barcelona
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato

Partner (1)